The calendar: two dates that matter
For anyone trading oncology names, the next five weeks come down to two events. Moderna and Merck plan to present detailed results for their personalized mRNA vaccine, intismeran, at ESMO on October 24, and to engage with regulators about potential filings.1 Separately, Summit Therapeutics' Biologics License Application for ivonescimab, based on HARMONi trial results, carries an FDA decision date (a PDUFA goal date) of November 14, 2026.1
The market already has one data point on the vaccine. On August 19, a personalized vaccine developed by Merck and Moderna was reported to have stopped melanoma from returning in a clinical trial described as historic.1 Our event record carries that headline but not the trial's numbers. October 24 is when the detail arrives, and that detail is what separates a headline from something you can value. Until then, what we can verify is the claim, not its size.
On October 2, Summit also announced a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to test ivonescimab alongside Datroway across multiple solid tumor settings, intending to include breast and lung cancer.1 The thesis in play is an antibody-drug conjugate paired with a bispecific antibody. No efficacy data for that pairing is in our dossier, so treat it as an announced plan, not a result.
The competitive backdrop in triple-negative breast cancer
Any first-line breast cancer combination will be measured against what is already moving. On July 24, the European Medicines Agency's CHMP adopted a positive opinion recommending Gilead's Trodelvy plus Keytruda in PD-(L)1-positive first-line metastatic triple-negative breast cancer.2 Gilead's release says the ASCENT-04/KEYNOTE-D19 trial showed a highly statistically significant and clinically meaningful reduction in the risk of disease progression or death.2 Evandro de Azambuja said that if authorized, Trodelvy plus Keytruda “would build on the recent approval of Trodelvy monotherapy and help establish a Trodelvy-based approach as a first-line treatment option across PD-L1 status.”2
That is a pattern, not a verdict on any one stock. In this setting an antibody-drug conjugate is being paired with an immunotherapy, and a rival conjugate-plus-bispecific is heading for its own FDA date. Our reading, which is analysis and not reported fact, is that Gilead's lead in this setting is what a Datroway-based combination would have to beat. Our dossier does not compare the two regimens' data, so we cannot say who is ahead.
A caution on the source: the Gilead release comes through NewsEOD, a feed where 56% of 4,956 checked claims have held up.2 That is a company press release carried by a feed that has been right a little more than half the time when checked. Read the trial results in the filing itself before acting on them.
Merck's checked numbers: more cost, less cash
Merck is the one large name here where we hold SEC-checked financials. The dossier does not include revenue, Keytruda sales or any oncology segment data, so we cannot say how profitable any of this is. What it does show is a company whose balance sheet moved sharply.
Cash at the end of the third quarter of 2025 was $18.169 billion.3 By the first quarter of 2026 it was $5.327 billion, and by the second quarter $6.849 billion.3 The full-year 2025 figure was $14.565 billion.3 To put the size in context: the drop from $18.2 billion to $5.3 billion is roughly two-thirds of the cash balance. The dossier does not say why, and we will not guess. Cash on a quarter-end date can swing for many reasons, including acquisitions, debt repayments or buybacks. Anyone holding Merck, directly or through an index fund that contains it, should look up the cause in the cash flow statement.
Costs rose over the same stretch. Merck's cost of revenue, the direct cost of making and selling its products, was $4.395 billion in the second quarter of 2026, against $3.557 billion in the second quarter of 2025.3 By our own arithmetic, that is up about 24%. The first quarter shows the same direction: $4.195 billion in 2026 against $3.419 billion in 2025, up about 23%.3 For scale, one quarter's cost of revenue now exceeds Merck's entire capital spending for 2025, which was $4.112 billion.3 Without revenue figures we cannot say whether sales rose faster than costs. That is the number to check first.
Capital spending moved more unevenly. Annual capex was $3.863 billion in 2023, $3.372 billion in 2024 and $4.112 billion in 2025.3 In the first quarter it was $861 million in 2024, $1.328 billion in 2025 and $991 million in 2026.3 Annual spending is up about 22% from 2024 to 2025, while the latest first quarter is about 25% below the year before. One quarter does not make a trend.
Commercial results: Novocure shows what a working launch looks like
The cleanest commercial datapoint in our dossier is Novocure. Its second-quarter 2026 net revenues were $184 million, up 16% year over year, driven by 18% growth in global active patients.4 The company also received a CE Mark for Optune Pax for locally advanced pancreatic cancer, with Germany the first EU market to launch, and reported more than 280 active patients on Optune Pax as of June 30, 2026.4 Frank Leonard said: “This was our strongest quarter to date, with record net revenues and active patients on therapy.”4 He added that the company is making material progress on its path to profitability.4 The $184 million is the company's figure, sourced to its own release. NewsEOD's measured hit rate on checked claims is 56%.4
Our narrative also notes that Kiniksa's Arcalyst revenue is growing and that Q2 oncology guidance was narrowed and raised. The dossier holds no figures behind either point, so we pass them on as context, not as findings.
The smaller names: runway matters more than science
The weaker side of the sector is also in view. ADC Therapeutics announced a workforce reduction it projects will deliver “$10 million in annualised cost savings,” and says it “maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations.”5 That is the company speaking about itself, in a roundup from a feed where 45% of 520 checked claims held up.5 For holders, the practical point is that a runway into 2028 buys time for combination data, but it is a management projection, not a guarantee. The narrative also records softer Q3 guidance from OPKO, with no detail in the dossier.
Elsewhere, Telix dosed the first patient in its Phase 3 LUTEON trial of TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma, described as the first radiopharmaceutical therapy to enter Phase 3 for that cancer.6 Aviral Singh said outcomes “remain poor for many patients.”6 This is a first-patient-dosed milestone, years from any approval decision. The source feed has the weakest record in this piece: 31% of 2,927 checked claims held up.6
The AI story: plausible, but this source has not earned trust
The narrative that ties these pieces together is that large pharma is putting AI into drug discovery. AstraZeneca's version is a “lab of the future.” Puja Sapra describes it this way: “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data.”7 She also says: “Data is our differentiator,” pointing to AstraZeneca's proprietary datasets on molecular structures, binding measurements, safety profiles and manufacturing outcomes.7
She is also candid about the limits. “One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body.”7 And “with more autonomous systems, human oversight remains at the heart of this approach.”7 Note what is missing: no drug, no trial result, no timeline. This is a description of method, not an earnings driver.
On reliability, the article, from MIT Technology Review and undated in our records, has a measured track record of 0% of 11 checked claims held up.7 That is a small sample, and it does not mean the quotes are fabricated. It means we could not confirm the claims against a source of truth, and you should weigh them accordingly. Our view is that the AI-discovery theme is real as a corporate strategy but unproven as a source of returns, and nothing in our dossier ties it to any specific revenue or approval.
What to watch
- October 24: the detailed intismeran data at ESMO, and whether Merck and Moderna announce regulatory engagement.1
- November 14: the FDA decision date for ivonescimab.1
- Merck's next filing: the reason for the cash drop from $18.169 billion, and whether revenue has kept pace with a roughly 24% rise in cost of revenue.3
- Gilead's Trodelvy plus Keytruda: the European Commission decision that follows CHMP's July 24 opinion.2
- ADC Therapeutics: whether the $10 million of projected annual savings shows up in reported costs.5
